Short-Term ALA Therapy Shows Renal Protection in Diabetic Nephropathy

Tags

Featured

Off

Page Content

#ffffff

Oxidative stress plays a central role in diabetic kidney injury. A recent study in the Journal of Diabetes and Its Complications evaluated whether ALA could restore antioxidant balance in this setting.

The randomized controlled trial enrolled 50 individuals with T1DM and DN who received either a 3-month ALA regimen (300 mg daily) or standard care. Outcomes were also compared with type 1 diabetes patients without nephropathy and healthy controls.

At baseline, those with DN showed higher MDA levels and lower TAC than the other groups. After ALA supplementation, participants demonstrated significant reductions in glycated hemoglobin,UAER, and MDA, alongside a marked increase in TAC.

Short-term ALA therapy lowers oxidative stress and reduces adverse renal biochemical markers in DN. It may serve as an adjunct treatment to protect kidney function in T1DM.

Anonymous user

Authenticated user

Premium

Paid / Sponsored

Key highlights

Alpha-lipoic acid (ALA) therapy was evaluated in patients with type 1 diabetes mellitus (T1DM) and diabetic nephropathy (DN).
Three months of ALA supplementation (300 mg/day) reduced malondialdehyde (MDA) and urinary albumin excretion rate (UAER) while increasing total antioxidant capacity (TAC).
Improvements in oxidative and glycemic markers suggest ALA as a potential adjunctive therapy to protect renal function in T1DM.

Source

Elhenawy YI, Thabet RA, Hegazy MGA, El-Morsy SA, Fereig YA. The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy in diabetic nephropathy among children and adolescents with type 1 diabetes: a randomized controlled trial. J Diabetes Complications. Published online November 4, 2025. doi:10.1016/j.jdiacomp.2025.109201

Thumbnail